

CLAIMS

1. A pharmaceutical composition for the prevention or the treatment of a disease associated with the excess of coupling factor-6 (CF6) in the blood which comprises a CF6 inhibitor as the active ingredient.
2. The pharmaceutical composition for the prevention or the treatment as claimed in claim 1 wherein said CF6 inhibitor is a CF6 secretion inhibitory substance or a CF6 antagonist.
3. A pharmaceutical composition for the prevention or the treatment as claimed in claim 1 or 2 wherein said disease associated with the excess of CF6 in the blood is heart infarction, angina pectoris, heart failure, pulmonary hypertension, hypertension, cerebrovascular disorder, arteriosclerosis obliterans, arteriosclerosis, hyperlipemia, diabetes, bronchial disease, stomach ulcer, eclampsia of pregnancy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura.
4. A pharmaceutical composition for the prevention or the treatment of a disease associated with the shortage of CF6 in the blood which comprises a CF6 activator or CF6 as the active ingredient.
5. The pharmaceutical composition for the prevention or the treatment as claimed in claim 4 wherein said CF6 activator is a CF6 secretion accelerating substance or a CF6 agonist.
6. The pharmaceutical composition for the prevention or the treatment as claimed in claim 4 or 5 wherein said

disease associated with the shortage of CF6 in the blood is an inflammatory disease such as brain infarction, acute pancreatitis, asthma, ARDS or rheumatoid arthritis.

7. A pharmaceutical composition for the prevention or the treatment of a disease associated with the shortage of PGI₂ and/or a disease associated with the attenuation of the Ca²⁺-dependent cytoplasmic PLA₂ (cPLA₂) function, which comprises a CF6 inhibitor as the active ingredient.

8. The pharmaceutical composition for the prevention or the treatment as claimed in claim 7 wherein said CF6 inhibitor is a CF6 secretion inhibitory substance or a CF6 antagonist.

9. A pharmaceutical composition for the prevention or the treatment as claimed in claim 7 or 8 wherein said disease associated with the shortage of PGI₂ and/or the disease associated with the attenuation of the cPLA₂ function is heart infarction, angina pectoris, heart failure, pulmonary hypertension, hypertension, cerebrovascular disorder, arteriosclerosis obliterans, arteriosclerosis, hyperlipemia, diabetes, bronchial disease, stomach ulcer, eclampsia of pregnancy, hemolytic-uremic syndrome or thrombocytopenic purpura.

10. A pharmaceutical composition for the prevention or the treatment of a disease associated with the excess of PGI₂ and/or a disease associated with cPLA₂ hyperfunction, which comprises a CF6 activator or CF6 as the active ingredient.

11. The pharmaceutical composition for the prevention or

the treatment as claimed in claim 10 wherein said CF6 activator is a CF6 secretion accelerating substance or a CF6 agonist.

12. A pharmaceutical composition for the prevention or the treatment as claimed in claim 10 or 11 wherein said disease associated with the shortage of PGI₂ and/or a disease associated with CPLA₂ hyperfunction is an inflammatory disease such as brain infarction, acute pancreatitis, asthma, ARDS or rheumatoid arthritis.

13. A method of diagnosing a disease associated with an increase or decrease in the CF6 level in the blood, characterized in that the CF6 level in a collected blood sample is measured.

14. A diagnostic aid comprising an anti-CF6 antibody which is used in a method of diagnosing a disease associated with an increase or decrease in the CF6 level in the blood, characterized in that the CF6 level in a collected blood sample is measured.

15. The diagnostic aid as claimed in claim 14 wherein said anti-CF6 antibody is prepared by using the whole human CF6 (SEQ ID NO:1) or rat CF6 (SEQ ID NO:2) or a part thereof as an antigen.

16. A method of producing CF6 or a polypeptide which is a part thereof by using gene recombination techniques, which comprises culturing a host having been transformed by a vector comprising a DNA encoding a chimeric protein wherein a polynucleotide sequence encoding said CF6 or a partial polypeptide thereof is bonded to a protective peptide via a

polynucleotide sequence encoding an enterokinase recognition site at the N-terminus, and treating the thus obtained chimeric protein with enterokinase to thereby give CF6 or the partial polypeptide thereof.

17. A diagnostic method of judging the susceptibility to a disease associated with an increase or decrease in the CF6 level in the blood, which involves the step of determining the presence/absence of a variation in a gene sequence in the CF6 gene domain in the genome of a patient.

18. The diagnostic method as claimed in claim 17 wherein said disease with an increase or decrease in the CF6 level in the blood is a disease associated with the shortage or excess of PGI_2 .

19. The diagnostic method as claimed in claim 17 wherein said disease with an increase or decrease in the CF6 level in the blood is a disease associated with the accentuation or attenuation of cPLA_2 function.

20. The diagnostic method as claimed in claim 13 wherein said disease with an increase or decrease in the CF6 level in the blood is acute heart infarction.